Colon Cancer Immunotherapy in India: Cost and Guide (2026)
Colon cancer immunotherapy in India costs USD 1,200–1,800 per cycle for MSI-H patients. Pembrolizumab at JCI hospitals. KEYNOTE-177 outcomes.Free opinion 48hrs.
Colon Cancer Immunotherapy in India: A Complete, Honest Guide for International Patients
Immunotherapy has changed the treatment of colon cancer dramatically — but only for a specific group of patients. It is not for everyone. It is for the approximately 5 percent of advanced colon cancer patients whose tumours carry a molecular characteristic called microsatellite instability-high, or MSI-H. For those patients, immunotherapy with pembrolizumab is not just an option — it is now the recommended first treatment, producing results that FOLFOX chemotherapy cannot match.
This guide explains what MSI-H means, why it makes colon cancer respond to immunotherapy, what the evidence shows, who qualifies, what the drugs available in India are, what they cost, and how to access this treatment as an international patient. The most important thing in this guide is not the section on hospitals or costs — it is the section on MSI testing. Everything else follows from that single test result.
KEYNOTE-177 trial results for pembrolizumab immunotherapy in MSI-H Stage 4 colon cancer — 16.5 months median progression-free survival versus 8.2 months on FOLFOX chemotherapy — and pembrolizumab cost comparison between India and the United States at JCI-accredited oncology centres.
- 1What MSI-H means and why it determines everything
- 2How checkpoint inhibitor immunotherapy works
- 3The KEYNOTE-177 trial — what it proved
- 4Immunotherapy drugs available in India
- 5Why immunotherapy does not work for MSS patients — and what does
- 6Side effects — how they differ from chemotherapy
- 7What immunotherapy costs in India vs the world
- 8How to get started as an international patient
Only patients whose tumours test MSI-H (microsatellite instability-high) or dMMR (mismatch repair deficient). For Stage 4 MSI-H patients, pembrolizumab is now the recommended first-line treatment per NCCN 2025 guidelines — producing 16.5 months median progression-free survival versus 8.2 months for FOLFOX chemotherapy. In India, pembrolizumab costs USD 1,200 to 1,800 per cycle — given every three weeks as a 30-minute outpatient infusion — compared to USD 10,000 to 16,000 per cycle in the United States. For MSS patients, checkpoint inhibitor immunotherapy currently has no proven benefit.
What MSI-H Means and Why It Determines Everything
Every cell in your body has a system for correcting mistakes that occur when DNA is copied — a system called mismatch repair. When a cell divides and copies its DNA, errors inevitably occur. Mismatch repair proteins — four of them, called MLH1, MSH2, MSH6, and PMS2 — patrol the newly copied DNA, identify errors, and fix them before the cell passes its DNA on to the next generation. It is a quality control system operating at the molecular level in every cell, every time a cell divides.
In some colon cancers, this mismatch repair system is defective. Either the genes that code for the repair proteins are mutated — as in Lynch syndrome, an inherited condition — or they are silenced by a chemical modification called methylation in a sporadic, non-inherited process. When the mismatch repair system is not working, errors in the DNA accumulate with every cell division. Over time, short repeated sequences in the DNA — called microsatellites — become highly unstable, varying in length from cell to cell. This is what MSI-H means: microsatellite instability-high. The technical equivalent term dMMR — deficient mismatch repair — means exactly the same thing.
Why does this DNA repair defect make cancer respond to immunotherapy? Because the accumulated mutations in MSI-H tumours produce a large number of abnormal proteins — called neoantigens — that the immune system can potentially recognise as foreign. MSI-H tumours are what immunologists call "immunogenic" — they look genuinely different from normal cells to an informed immune system. This is why immunotherapy, which removes the brakes that prevent immune attack, is so dramatically effective in MSI-H tumours: there is a genuine target for the immune response to pursue.
MSS tumours — microsatellite stable — have a functional mismatch repair system. They accumulate far fewer mutations, produce fewer neoantigens, and are effectively invisible to the immune system even when checkpoint brakes are removed. This is why pembrolizumab simply does not work for MSS colon cancer — not because the drug is inadequate, but because there is no immunogenic target for it to reveal.
Giving pembrolizumab to a patient with MSS colon cancer is not merely ineffective — it delays the effective treatment, exposes the patient to immune-related toxicity risks, and costs USD 10,000 to 16,000 per cycle for a drug that provides no benefit in that patient. The converse error — starting a confirmed MSI-H patient on FOLFOX chemotherapy instead of pembrolizumab — deprives them of a treatment that produces twice the progression-free survival of chemotherapy. Both errors require the same prevention: test MSI status first, always, before any treatment decision in Stage 3 or Stage 4 colon cancer.
Arrange MSI testing from your existing biopsy tissue
GAF Healthcare can arrange MSI/MMR testing at a CAP-accredited Indian laboratory from your archived biopsy tissue blocks — without you travelling. Ship your tissue blocks, receive your MSI result within 7 to 10 days, and know whether immunotherapy is relevant for your case before making any treatment decision.
Arrange MSI Testing →How Checkpoint Inhibitor Immunotherapy Works
The immune system can kill cancer cells. This is not a new discovery — it has been observed since the late nineteenth century that some cancers occasionally regress spontaneously in patients who develop severe infections, suggesting their immune system's activation against the infection somehow attacked the tumour as well. The challenge was never making the immune system capable of attacking cancer. The challenge was understanding why it was not doing so already — and what was stopping it.
The answer turns out to be a system of molecular brakes built into the immune response to prevent it from attacking normal healthy tissue. These brakes — called immune checkpoints — are essential for preventing autoimmune disease. Cancer cells have learned to exploit these brakes. Colon cancer cells produce a protein called PD-L1 on their surface, which binds to a receptor called PD-1 on immune T-cells. When PD-L1 binds PD-1, the T-cell receives a signal that says: "Stand down. This is not a threat." The cancer cell disguises itself as normal tissue and the immune system ignores it.
Pembrolizumab is a monoclonal antibody that blocks the PD-1 receptor on T-cells. By blocking PD-1, pembrolizumab prevents cancer cells from sending the "stand down" signal. The T-cells remain active and can recognise the cancer's abnormal proteins — the neoantigens produced by the accumulated mutations in MSI-H tumours — as foreign and attack them. This is why the term "checkpoint inhibitor" is used: the drug inhibits the checkpoint that was preventing the immune attack.
The practical implications of this mechanism are significant for patients. Because pembrolizumab works by restoring the immune system's natural ability to attack cancer — rather than by directly poisoning cells with cytotoxic drugs — its effect can be durable in ways that chemotherapy is not. Some MSI-H patients who achieve a complete response to pembrolizumab maintain that response for years after the drug is stopped. This kind of durable complete response is essentially never seen with FOLFOX chemotherapy. The immune system, once appropriately activated against a specific tumour, can maintain surveillance and suppress regrowth in a way that no chemotherapy drug can replicate.
A complete response means that all measurable tumour deposits have disappeared on imaging — CT scans and PET scans show no evidence of active cancer. In KEYNOTE-177, a meaningful proportion of MSI-H Stage 4 colon cancer patients achieved complete responses on pembrolizumab. Some of these patients have remained in complete response for three to five years after stopping treatment. In a disease where the standard prognosis was median survival of 12 to 18 months before the era of targeted therapy, these durable complete responses represent genuine long-term cure for a minority of MSI-H patients — something that FOLFOX chemotherapy never achieved.
The KEYNOTE-177 Trial — What It Proved
KEYNOTE-177 is the randomised controlled trial that established pembrolizumab as first-line treatment for MSI-H Stage 4 colon cancer. Published in the New England Journal of Medicine in 2020 and updated with longer follow-up data subsequently, it is the most important piece of evidence for any MSI-H colon cancer patient considering immunotherapy in India or anywhere else.
The trial enrolled 307 previously untreated patients with MSI-H or dMMR Stage 4 colorectal cancer and randomised them to pembrolizumab 200 mg every three weeks, or to standard chemotherapy — the investigator's choice of FOLFOX or FOLFIRI plus bevacizumab or cetuximab depending on RAS status. The results were unambiguous in favour of pembrolizumab.
| Outcome measure | Pembrolizumab | FOLFOX/FOLFIRI chemotherapy |
|---|---|---|
| Median progression-free survival | 16.5 months | 8.2 months |
| Progression-free at 24 months | 43% | 33% |
| Overall response rate | 44% | 33% |
| Complete response rate | 11% | 4% |
| Grade 3–4 adverse events | 22% | 66% |
| Treatment discontinuation due to adverse events | 9% | 12% |
| Median overall survival | Not reached at median follow-up | 36.7 months |
Source: André T et al. KEYNOTE-177: Pembrolizumab versus chemotherapy in MSI-H/dMMR colorectal cancer. New England Journal of Medicine 2020. Updated survival analysis 2022.
The grade 3 to 4 adverse events finding in the table above deserves specific attention. Pembrolizumab produced serious adverse events in 22 percent of patients — versus 66 percent for FOLFOX or FOLFIRI chemotherapy. This means that three times as many patients experienced serious toxicity on chemotherapy as on immunotherapy. For patients from resource-limited settings where managing severe chemotherapy complications is particularly challenging, this difference is practically significant beyond the survival benefit.
The overall survival data from KEYNOTE-177 is notable for a different reason. The median overall survival had not been reached in the pembrolizumab arm at the time of the updated analysis — meaning more than half of the patients were still alive. This is an extraordinary finding for Stage 4 colorectal cancer, a disease where median survival with chemotherapy had historically been measured in months to a few years.
Know your MSI status before you start any treatment
If you have Stage 3 or Stage 4 colon cancer and have not had MSI testing, send your biopsy tissue blocks to GAF Healthcare. We arrange CAP-accredited MSI testing in India at USD 80 to 140. Results in 7 to 10 days. Your entire treatment plan may change depending on the result.
Immunotherapy Drugs Available in India for MSI-H Colon Cancer
India's major oncology centres have access to the full range of checkpoint inhibitor immunotherapy drugs approved for colon cancer by international regulatory agencies. The following drugs are available at GAF Healthcare's partner hospitals in India.
Pembrolizumab (Keytruda)
PD-1 inhibitor. FDA and EMA approved as first-line treatment for MSI-H Stage 4 colorectal cancer. Established as standard of care by KEYNOTE-177. Given as 200 mg IV infusion every 3 weeks or 400 mg every 6 weeks. Duration: until disease progression or 2 years, whichever comes first.
Nivolumab (Opdivo)
PD-1 inhibitor. Similar mechanism to pembrolizumab. Used as second-line treatment for MSI-H colorectal cancer and in combination with ipilimumab. The nivolumab plus ipilimumab combination — dual checkpoint blockade — has shown higher response rates than nivolumab alone in MSI-H colorectal cancer in the CheckMate 142 trial.
Nivolumab + Ipilimumab
Dual checkpoint blockade. Ipilimumab blocks CTLA-4, a different immune checkpoint from PD-1. The combination activates the immune response through two independent pathways simultaneously, producing higher response rates of 55 percent versus 31 percent for nivolumab alone in the CheckMate 142 trial. Higher toxicity rate than single-agent pembrolizumab.
Chemo + Immunotherapy (MSS)
Multiple trials are investigating whether adding immunotherapy to chemotherapy converts MSS colon cancer into an immunotherapy-responsive disease — by increasing tumour mutation burden. Results so far have been disappointing for unselected MSS patients. Do not accept immunotherapy combination treatment for MSS colon cancer outside of a formal clinical trial.
Pembrolizumab can be given as a 400 mg dose every six weeks — an FDA-approved alternative to 200 mg every three weeks with equivalent efficacy. For international patients who are managing treatment in a split pathway — partly in India, partly at home — the six-weekly schedule means six infusions per year instead of seventeen. This significantly reduces the travel burden for patients who continue pembrolizumab in India. Ask your oncologist specifically about the six-weekly schedule if returning to India for every three-weekly infusions is not practical.
Why Immunotherapy Does Not Work for MSS Patients — and What Does
If you have just been told your tumour is MSS — microsatellite stable — this section is the most important one for you. MSS means the standard immunotherapy drugs that work so dramatically for MSI-H patients are not effective for your cancer. Understanding why, and what does work for you, is essential.
MSS colon cancers have a functioning mismatch repair system. They accumulate fewer mutations, produce fewer abnormal proteins, and are effectively invisible to the immune system even when checkpoint brakes like PD-1 are removed. Multiple clinical trials have confirmed that single-agent PD-1 or PD-L1 inhibitors — pembrolizumab, nivolumab, atezolizumab, durvalumab — produce response rates below 5 percent in MSS colorectal cancer. This is not a treatment failure — it is a predictable biological result of treating a non-immunogenic tumour with a drug that works by exposing it to immune recognition.
For MSS Stage 4 colon cancer, the correct treatment pathway in India is chemotherapy combined with targeted therapy. The choice of targeted agent depends on your molecular profile — specifically your RAS and BRAF mutation status. Bevacizumab is added for all MSS patients regardless of RAS status. Cetuximab or panitumumab is added for MSS patients who are RAS wild-type with a left-sided primary tumour. BRAF V600E mutant MSS patients receive the encorafenib plus cetuximab combination as second-line treatment. None of these patients should be receiving pembrolizumab.
Get a second opinion before starting. Single-agent checkpoint inhibitor immunotherapy for MSS colorectal cancer has no proven benefit outside clinical trials. If the recommendation is for a combination of immunotherapy plus chemotherapy, ask whether this is part of a formal registered clinical trial — if not, the evidence base for this approach is not established. GAF Healthcare can arrange a written second opinion from a GI medical oncologist at an Indian partner hospital within 48 hours. This review is free and could prevent you from receiving a treatment that will not help you.
Covers treatment options for both MSI-H and MSS colon cancer by stage — including chemotherapy protocols, targeted therapy, HIPEC, and the full international patient pathway.
Side Effects — How They Differ from Chemotherapy
The side effect profile of pembrolizumab immunotherapy is fundamentally different from FOLFOX chemotherapy — different in character, different in timing, and for most patients significantly more manageable. Understanding this difference removes a great deal of the anxiety patients feel when they hear "immunotherapy."
Chemotherapy side effects occur because cytotoxic drugs damage rapidly dividing cells throughout the body — not just cancer cells. Hair follicles, the lining of the gut, and the bone marrow all divide rapidly, which is why FOLFOX causes nausea, mouth sores, peripheral neuropathy, and low blood counts. These effects are predictable, dose-dependent, and occur in almost every patient to some degree.
Immunotherapy side effects are caused by something different — the immune system being activated not just against the cancer but also against normal tissues. These are called immune-related adverse events — irAEs — and they occur in a minority of patients, in unpredictable tissues, at unpredictable times. They require a different mindset from chemotherapy toxicity management: instead of expecting nausea and managing it with anti-emetics, the approach is to watch for unexpected symptoms in any organ system and report them promptly.
| Immune-related adverse event | Frequency | Symptoms to watch for | Management |
|---|---|---|---|
| Thyroid dysfunction | 10–15% | Fatigue, weight change, temperature sensitivity, palpitations | Thyroid hormone replacement or antithyroid medication. Pembrolizumab usually continued. |
| Skin rash / dermatitis | 10–15% | Rash, itching, blistering — usually mild and manageable | Topical corticosteroids for mild cases. Oral steroids for Grade 2+. Usually continues. |
| Hepatitis (liver inflammation) | 5–8% | Abnormal liver function tests — usually detected by monitoring blood tests | Corticosteroids. Pembrolizumab held until resolved. Rarely requires permanent discontinuation. |
| Colitis (bowel inflammation) | 3–5% | Diarrhoea, abdominal cramping — report immediately if severe | Corticosteroids. Pembrolizumab held. May require infliximab if steroid-refractory. |
| Pneumonitis (lung inflammation) | 2–4% | New or worsening cough, breathlessness, chest tightness | Pembrolizumab held immediately. High-dose corticosteroids. Permanent discontinuation if severe. |
| Arthritis / joint pain | 3–6% | Joint swelling, pain, stiffness — especially in small joints of hands | NSAIDs, corticosteroids, rheumatology referral. Pembrolizumab usually continued. |
Sources: KEYNOTE-177 safety data (NEJM 2020) · NCCN Management of Immunotherapy-Related Toxicities Guidelines 2025 · GAF Healthcare clinical protocol documentation
The key practical point for international patients managing pembrolizumab at home: immune-related adverse events can occur at any time — including months after the last infusion. If you develop any new symptom that is unexpected or persistent while receiving pembrolizumab or within three months of stopping it, it should be reported to your oncologist promptly as a possible immune-related adverse event. Do not wait to see if it resolves on its own. Early treatment with corticosteroids prevents most irAEs from becoming serious.
What Immunotherapy Costs in India vs the World
The cost difference between pembrolizumab in India and in Western countries is among the largest of any cancer treatment comparison. The drug itself is manufactured by Merck — MSD outside the United States — and is not yet available as a biosimilar, meaning the savings in India come from lower hospital infrastructure costs, lower infusion nursing costs, and lower institutional markups on the drug cost rather than from a generic equivalent.
| Country | Per cycle cost | Annual cost (17 cycles) | Notes |
|---|---|---|---|
| India | $1,200 – $1,800 | $20,400 – $30,600 | JCI/NABH hospitals. Includes drug, infusion, monitoring. |
| UAE | $5,000 – $8,000 | $85,000 – $136,000 | Available at major private centres. |
| Thailand | $4,000 – $6,500 | $68,000 – $110,500 | Available at Bumrungrad and select centres. |
| UK (private) | £7,500 – £12,000 | £127,500 – £204,000 | NHS may fund if NICE approved. Private significantly higher. |
| USA | $10,000 – $16,000 | $170,000 – $272,000 | Out-of-pocket for international patients without US insurance. |
Sources: GAF Healthcare Hospital Cost Database 2026 · Apollo, Medanta, Fortis oncology tariffs · CMS Hospital Price Transparency Data USA 2026 · NHS England Pembrolizumab tariff 2025
Planning the cost of ongoing pembrolizumab treatment
Unlike FOLFOX chemotherapy — which has a fixed duration of six months for adjuvant treatment — pembrolizumab for Stage 4 MSI-H colon cancer continues until disease progression or for a maximum of two years in patients who achieve complete or sustained response. This means the total cost is not fixed in advance. A patient who responds well and continues for two years in India at USD 1,500 per cycle every three weeks spends approximately USD 39,000 over the treatment period. A patient whose disease progresses after six months of treatment spends approximately USD 9,000 to 10,800.
For international patients, the most practical approach is to start pembrolizumab in India and then assess whether continuation in India, at home, or on a hybrid schedule is most cost-effective and logistically feasible. Countries where pembrolizumab is unavailable locally — many parts of sub-Saharan Africa — mean patients must continue in India or in another accessible country. Countries where pembrolizumab is available but expensive locally — UAE, Gulf states, UK privately — mean India remains significantly cheaper for the ongoing treatment. GAF Healthcare helps patients model the total cost of their treatment plan under different scenarios before they start.
"I was started on FOLFOX in Lagos before anyone tested my MSI status. When I arrived at Medanta, they tested my tissue and found I was MSI-H. They stopped the FOLFOX immediately and started me on pembrolizumab. My scans at six months showed a near-complete response. The oncologist said if I had known this from the start, I would never have had chemotherapy at all."
Full itemised cost reference for all colon cancer treatment options in India — including pembrolizumab, nivolumab, FOLFOX, bevacizumab, and encorafenib — with country-by-country comparisons.
Get a personalised immunotherapy cost plan for your case
Cost depends on your dosing schedule — every 3 weeks or every 6 weeks — how many cycles you complete in India, and whether continuation at home is feasible. Send your MSI result and GAF Healthcare will model your complete treatment cost under different scenarios within 48 hours.
Get My Immunotherapy Cost Plan →How to Get Started as an International Patient
The sequence is critical. Step one is always MSI testing — not hospital selection, not visa application, not booking flights. The MSI result determines your entire treatment pathway. Everything else comes after.
-
1
MSI testing — from your existing tissue blocks
If you have not had MSI/MMR testing, ship your archived biopsy tissue blocks to India. GAF Healthcare coordinates with a CAP-accredited laboratory. Cost is USD 80 to 140. Results in 7 to 10 days. If MSI-H — pembrolizumab pathway. If MSS — molecular profiling for KRAS, NRAS, BRAF, HER2 and chemotherapy pathway.
-
2
Receive immunotherapy protocol recommendation within 48 hours
For confirmed MSI-H patients, GAF Healthcare forwards your complete records to a GI medical oncologist at a matched hospital. You receive a written pembrolizumab protocol recommendation — dosing schedule, monitoring plan, total estimated cost — within 48 hours. No payment required at this stage.
-
3
Medical visa and travel planning
India's e-Medical Visa is valid for one year with multiple entries — essential for patients on ongoing pembrolizumab who will return to India for infusions. GAF Healthcare provides the hospital visa support letter. If using the six-weekly schedule, you visit India approximately eight to nine times per year rather than seventeen.
-
4
Arrival and pre-treatment assessment
Airport transfer arranged. Within 24 to 48 hours the oncologist reviews your records, confirms MSI status, performs baseline blood tests and CT staging, and reviews your fitness for pembrolizumab. If all is confirmed, the first infusion is scheduled within 5 to 7 days of arrival. The infusion itself takes 30 minutes as an outpatient procedure.
-
5
Start pembrolizumab — complete first 2 to 4 cycles in India
The first two to four infusions are completed in India to establish tolerability and confirm early response. Response assessment CT scan is typically done after cycle 4 — at approximately 12 weeks. If responding, you receive the full protocol for continuation at home or return to India on the schedule agreed with your oncologist.
-
6
Ongoing treatment — in India, at home, or hybrid
Your India oncologist is available for video consultation throughout treatment. Surveillance CT scans every 12 to 16 weeks monitor response. If continuing at home, the protocol — drug name, dose, schedule, pre-medications, and monitoring blood test requirements — is provided in a discharge package your local oncologist can implement. GAF Healthcare coordinates communication between your India and home teams throughout the treatment course.
Test first. Then treat. It changes everything.
Send your biopsy tissue blocks or existing MSI result, staging scans, and pathology. Within 48 hours you will have a written treatment recommendation — immunotherapy protocol if MSI-H, or the correct chemotherapy and targeted agent protocol if MSS. From a GI medical oncologist. Free. No obligation.